MINNEAPOLIS, Jan. 25,
2024 /PRNewswire/ -- Bio-Techne Corporation
(NASDAQ: TECH) today announced that its spatial biology brands,
Lunaphore and Advanced Cell Diagnostics (ACD), will launch the
first fully automated spatial multiomics workflow with same-section
hyperplex detection of RNA and protein biomarkers. This
state-of-the-art solution revolutionizes the field of predictive
biomarker research and drug development. The best-in-class
multiomics solution leverages ACD's RNAscope™ HiPlex RNA detection
and Lunaphore's universal multiplex sequential immunofluorescence
(seqIF™) technology on the COMET™ platform, which performs protein
detection with standard, non-conjugated antibodies. The multiomics
application will be commercially available in Q2 2024.
Until now, researchers have faced challenges in integrating
critical spatial information and accessing true multi-modal,
same-cell analysis with full workflow automation. The Company's new
multiomics solution for translational research overcomes this gap
by enabling the correlation of RNA and protein data at the
subcellular level in its spatial tissue context without any user
intervention and with the highest throughput in the hyperplex
market. This fully automated workflow enables researchers and
clinicians to generate highly robust data through reliable and
reproducible target detection. It offers complete flexibility in
panel design by selecting any protein target with the use of
standard reagents, including clinically proven IHC antibodies and
RNAscope.
"Combining ACD's leading RNA detection technology with
Lunaphore's fully automated high-throughput protein detection
capabilities on the COMET system enables a best-in-class multiomics
spatial biology solution," commented Kim
Kelderman, Bio-Techne's Chief Operating Officer. "We remain
focused on delivering breakthrough spatial technologies that
empower researchers and clinicians to push boundaries in healthcare
and ultimately improve patient outcomes. With this cutting-edge
application, we continue to lead the way and shape the future of
the spatial biology market."
The complete multiomics solution will be showcased through a
series of activities at the Lunaphore Suite, Curacao 4, at the Advances in Genome
Biology and Technology (AGBT) 2024 General Meeting, taking
place February 5-8, in Orlando, Florida. To book a meeting or find
out more about Lunaphore and ACD's presence at the conference,
please visit Lunaphore's website.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH)
is a global life sciences company providing innovative tools and
bioactive reagents for the research and clinical diagnostic
communities. Bio-Techne products assist scientific investigations
into biological processes and the nature and progress of specific
diseases. They aid in drug discovery efforts and provide the means
for accurate clinical tests and diagnoses. With thousands of
products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has
approximately 3,100 employees worldwide. For more information on
Bio-Techne and its brands, please visit https://www.bio-techne.com
or follow the Company on social media at: Facebook, LinkedIn,
Twitter or YouTube.
About COMET™
COMET™ is the only fully automated,
high-throughput, hyperplex platform ensuring scalability and
reproducibility without the need to conjugate primary antibodies.
COMET™ provides walk-away automation, integrating staining,
imaging, and image preprocessing steps to obtain standard hyperplex
images. The multiomics capability of COMET™ enables the
simultaneous analysis of both RNA and protein data within the
spatial context of tissues to enhance the understanding of cellular
dynamics and disease processes. COMET™ generates highly robust and
reproducible data with full tissue preservation, allowing
researchers to perform downstream modalities such as H&E or
transcriptomics using the same slide. Its superior tissue profiling
capabilities facilitate the analysis of 40 different spatial
markers in each automated run on a tissue slide. In contrast to
other spatial biology solutions, COMET™ works with off-the-shelf,
label-free primary antibodies, making panel design much more
flexible and faster than any other hyperplex solution. COMET™ works
with regular glass slides from standard histology workflows; it is
validated for human and mouse samples and is compatible with any
other animal sample. The platform can be used for a wide range of
research applications, allowing for a dramatic improvement in the
understanding of disease pathology. To learn more about the COMET™
platform, please visit: https://lunaphore.com/products/comet/
For further information on Lunaphore:
Lindsey Rodger, Head of Communications
communications@lunaphore.com
Bio-Techne Corporation (NASDAQ: TECH)
David Clair, Vice President, Investor Relations
& Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lunaphore-and-acd-revolutionize-spatial-biology-research-with-the-launch-of-the-first-fully-automated-same-section-hyperplex-multiomics-application-302040724.html
SOURCE Bio-Techne Corporation